- Home
- ATOS vs KLRS Comparison
ATOS vs KLRS Comparison
Compare ATOS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- KLRS
- Stock Information
- Founded
- ATOS 2009
- KLRS 2019
- Country
- ATOS United States
- KLRS United States
- Employees
- ATOS N/A
- KLRS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATOS Health Care
- KLRS Health Care
- Exchange
- ATOS Nasdaq
- KLRS Nasdaq
- Market Cap
- ATOS 112.5M
- KLRS 129.0M
- IPO Year
- ATOS 2012
- KLRS N/A
- Fundamental
- Price
- ATOS $0.85
- KLRS $2.50
- Analyst Decision
- ATOS Strong Buy
- KLRS Buy
- Analyst Count
- ATOS 3
- KLRS 1
- Target Price
- ATOS $6.17
- KLRS N/A
- AVG Volume (30 Days)
- ATOS 1.5M
- KLRS 39.9K
- Earning Date
- ATOS 08-11-2025
- KLRS 08-15-2025
- Dividend Yield
- ATOS N/A
- KLRS N/A
- EPS Growth
- ATOS N/A
- KLRS N/A
- EPS
- ATOS N/A
- KLRS N/A
- Revenue
- ATOS N/A
- KLRS N/A
- Revenue This Year
- ATOS N/A
- KLRS N/A
- Revenue Next Year
- ATOS N/A
- KLRS N/A
- P/E Ratio
- ATOS N/A
- KLRS N/A
- Revenue Growth
- ATOS N/A
- KLRS N/A
- 52 Week Low
- ATOS $0.55
- KLRS $2.28
- 52 Week High
- ATOS $1.66
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- ATOS 51.17
- KLRS N/A
- Support Level
- ATOS $0.81
- KLRS N/A
- Resistance Level
- ATOS $0.92
- KLRS N/A
- Average True Range (ATR)
- ATOS 0.05
- KLRS 0.00
- MACD
- ATOS -0.00
- KLRS 0.00
- Stochastic Oscillator
- ATOS 52.73
- KLRS 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.